{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T01:24:12Z","timestamp":1766712252729,"version":"3.41.2"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T00:00:00Z","timestamp":1519603200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81630061","81473255"],"award-info":[{"award-number":["81630061","81473255"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2017-I2M-1-014"],"award-info":[{"award-number":["2017-I2M-1-014"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"DOI":"10.3389\/fcimb.2018.00051","type":"journal-article","created":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T05:49:06Z","timestamp":1519624146000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket"],"prefix":"10.3389","volume":"8","author":[{"given":"Xiujuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanmei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huihui","family":"Chong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinsheng","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinquan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxian","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,2,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1107\/S0907444902016657","article-title":"PHENIX: building new software for automated crystallographic structure determination","volume":"58","author":"Adams","year":"2002","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1016\/j.020","article-title":"Multifaceted action of Fuzeon as virus-cell membrane fusion inhibitor","volume":"1808","author":"Ashkenazi","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1093\/jac\/dkt529","article-title":"Improvement of HIV fusion inhibitor C34 efficacy by membrane anchoring and enhanced exposure","volume":"69","author":"Augusto","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"12428","DOI":"10.1128\/JVI.78.22.12428-12437.2004","article-title":"Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor","volume":"78","author":"Baldwin","year":"2004","journal-title":"J. Virol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.coviro.2012.01.002","article-title":"Is there a future for antiviral fusion inhibitors?","volume":"2","author":"Berkhout","year":"2012","journal-title":"Curr. Opin. Virol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.antiviral.2011.04.002","article-title":"Molecular strategies to design an escape-proof antiviral therapy","volume":"92","author":"Berkhout","year":"2011","journal-title":"Antiviral Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"15613","DOI":"10.1073\/pnas.95.26.15613","article-title":"Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target","volume":"95","author":"Chan","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0092-8674(00)80205-6","article-title":"Core structure of gp41 from the HIV envelope glycoprotein","volume":"89","author":"Chan","year":"1997","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0092-8674(00)81430-0","article-title":"HIV entry and its inhibition","volume":"93","author":"Chan","year":"1998","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"6563","DOI":"10.1128\/JVI.02546-06","article-title":"Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue","volume":"81","author":"Chinnadurai","year":"2007","journal-title":"J. Virol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1742-4690-11-40","article-title":"Two M-T hook residues greatly improve the antiviral activity and resistance profile of the HIV-1 fusion inhibitor SC29EK","volume":"11","author":"Chong","year":"","journal-title":"Retrovirology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"6378","DOI":"10.1021\/acs.jmedchem.5b00109","article-title":"The N-terminal T-T motif of a third-generation HIV-1 fusion inhibitor is not required for binding affinity and antiviral activity","volume":"58","author":"Chong","year":"","journal-title":"J. Med. Chem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/QAD.0000000000000498","article-title":"Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket","volume":"29","author":"Chong","year":"","journal-title":"AIDS"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1097\/QAD.0000000000001073","article-title":"Development of potent and long-acting HIV-1 fusion inhibitors","volume":"30","author":"Chong","year":"2016","journal-title":"AIDS"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e00288","DOI":"10.1128\/JVI.00288-17","article-title":"A lipopeptide HIV-1\/2 fusion inhibitor with highly potent in vitro, ex vivo and in vivo antiviral activity","volume":"91","author":"Chong","year":"2017","journal-title":"J. Virol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1093\/jac\/dku183","article-title":"The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance","volume":"69","author":"Chong","year":"","journal-title":"J. Antimicrob. Chemother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1096\/fj.12-222547","article-title":"Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1","volume":"27","author":"Chong","year":"2013","journal-title":"FASEB J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"34558","DOI":"10.1074\/jbc.M112.390393","article-title":"The M-T hook structure is critical for design of HIV-1 fusion inhibitors","volume":"287","author":"Chong","year":"","journal-title":"J. Biol. Chem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e32599","DOI":"10.1371\/journal.pone.0032599","article-title":"Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor","volume":"7","author":"Chong","year":"","journal-title":"PLoS ONE"},{"key":"B20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nrm1076","article-title":"The structural biology of type I viral membrane fusion","volume":"4","author":"Colman","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"12772","DOI":"10.1073\/pnas.0701478104","article-title":"Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus","volume":"104","author":"Dwyer","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1146\/annurev.biochem.70.1.777","article-title":"Mechanisms of viral membrane fusion and its inhibition","volume":"70","author":"Eckert","year":"2001","journal-title":"Annu. Rev. Biochem."},{"key":"B23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0092-8674(00)80066-5","article-title":"Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket","volume":"99","author":"Eckert","year":"1999","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","first-page":"6678","DOI":"10.1128\/JVI.00352-08","article-title":"Selection of T1249-resistant human immunodeficiency virus type 1 variants","volume":"82","author":"Eggink","year":"2008","journal-title":"J. Virol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.2174\/138161210794079218","article-title":"Inhibition of HIV-1 by fusion inhibitors","volume":"16","author":"Eggink","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"B26","doi-asserted-by":"publisher","first-page":"10785","DOI":"10.1128\/JVI.05331-11","article-title":"Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function","volume":"85","author":"Eggink","year":"2011","journal-title":"J. Virol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"26941","DOI":"10.1074\/jbc.M109.004416","article-title":"Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors","volume":"284","author":"Eggink","year":"2009","journal-title":"J. Biol. Chem."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e01554","DOI":"10.1128\/JVI.01554-16","article-title":"In vivo efficacy of measles virus fusion protein-derived peptides is modulated by the properties of self-assembly and membrane residence","volume":"91","author":"Figueira","year":"2017","journal-title":"J. Virol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/jac\/dkh330","article-title":"Resistance to enfuvirtide, the first HIV fusion inhibitor","volume":"54","author":"Greenberg","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.2174\/1381612811319100004","article-title":"Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusion","volume":"19","author":"He","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"B32","doi-asserted-by":"publisher","first-page":"6349","DOI":"10.1128\/JVI.00319-08","article-title":"Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors","volume":"82","author":"He","year":"","journal-title":"J. Virol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"16332","DOI":"10.1073\/pnas.0807335105","article-title":"Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains","volume":"105","author":"He","year":"","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B34","doi-asserted-by":"publisher","first-page":"11126","DOI":"10.1074\/jbc.M800200200","article-title":"Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor","volume":"283","author":"He","year":"","journal-title":"J. Biol. Chem."},{"key":"B35","doi-asserted-by":"publisher","first-page":"7582","DOI":"10.1128\/JVI.78.14.7582-7589.2004","article-title":"Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site","volume":"78","author":"Heil","year":"2004","journal-title":"J. Virol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.1073\/pnas.0901007106","article-title":"Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency","volume":"106","author":"Ingallinella","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B37","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/protein\/gzs051","article-title":"Generation of a dual-functional split-reporter protein for monitoring membrane fusion using self-associating split GFP","volume":"25","author":"Ishikawa","year":"2012","journal-title":"Protein Eng. Des. Sel."},{"key":"B38","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1128\/AAC.48.11.4349-4359.2004","article-title":"N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion","volume":"48","author":"Jiang","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/3293","article-title":"Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry","volume":"4","author":"Kilby","year":"1998","journal-title":"Nat. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1056\/NEJMoa035026","article-title":"Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America","volume":"348","author":"Lalezari","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1107\/S0021889892009944","article-title":"PROCHECK: a program to check the stereochemical quality of protein structures","volume":"26","author":"Laskowski","year":"1993","journal-title":"J. Appl. Crystallogr."},{"key":"B42","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1074\/jbc.M110.199323","article-title":"In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor","volume":"286","author":"Liu","year":"2011","journal-title":"J. Biol. Chem."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.3390\/v2051069","article-title":"HIV-1 Entry, inhibitors, and resistance","volume":"2","author":"Lobritz","year":"2010","journal-title":"Viruses"},{"key":"B44","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd1331","article-title":"Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes","volume":"3","author":"Matthews","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"B45","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J. Appl. Crystallogr."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1128\/AAC.01211-08","article-title":"SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide","volume":"53","author":"Naito","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"B47","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1128\/JVI.79.2.764-770.2005","article-title":"Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions","volume":"79","author":"Nameki","year":"2005","journal-title":"J. Virol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1002\/1521-3773(20020816)41:16<2937::AID-ANIE2937>3.0.CO;2-J","article-title":"Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells","volume":"41","author":"Otaka","year":"2002","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"B49","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","article-title":"Processing of X-ray diffraction data collected in oscillation mode","volume":"276","author":"Otwinowski","year":"1997","journal-title":"Meth. Enzymol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/psc.2706","article-title":"Cholesterol-conjugated peptide antivirals: a path to a rapid response to emerging viral diseases","volume":"21","author":"Pessi","year":"2015","journal-title":"J. Pept. Sci."},{"key":"B51","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1128\/JVI.72.2.986-993.1998","article-title":"Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides","volume":"72","author":"Rimsky","year":"1998","journal-title":"J. Virol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"39471","DOI":"10.1074\/jbc.M110.145789","article-title":"Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors","volume":"285","author":"Shimura","year":"2010","journal-title":"J. Biol. Chem."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1097\/00002030-200409030-00007","article-title":"Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates","volume":"18","author":"Sista","year":"2004","journal-title":"AIDS"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.2174\/138161210790963751","article-title":"Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins","volume":"16","author":"Steffen","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"B55","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1097\/QAD.0000000000001415","article-title":"A novel HIV-1 gp41 tripartite model for rational design of HIV-1 fusion inhibitors with improved antiviral activity","volume":"31","author":"Su","year":"","journal-title":"AIDS"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e01445","DOI":"10.1128\/JVI.01445-16","article-title":"Creating an Artificial tail anchor as a novel strategy to enhance the potency of peptide-based HIV fusion inhibitors","volume":"91","author":"Su","year":"","journal-title":"J. Virol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.1128\/JVI.00373-15","article-title":"Mechanism of HIV-1 resistance to short-peptide fusion inhibitors targeting the Gp41 pocket","volume":"89","author":"Su","year":"","journal-title":"J. Virol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"12467","DOI":"10.1128\/JVI.01741-15","article-title":"Genetic pathway of HIV-1 resistance to novel fusion inhibitors targeting the Gp41 pocket","volume":"89","author":"Su","year":"","journal-title":"J. Virol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"12303","DOI":"10.1073\/pnas.94.23.12303","article-title":"Atomic structure of a thermostable subdomain of HIV-1 gp41","volume":"94","author":"Tan","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B60","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/387426a0","article-title":"Atomic structure of the ectodomain from HIV-1 gp41","volume":"387","author":"Weissenhorn","year":"1997","journal-title":"Nature"},{"key":"B61","doi-asserted-by":"publisher","first-page":"16828","DOI":"10.1073\/pnas.0708109104","article-title":"Potent D-peptide inhibitors of HIV-1 entry","volume":"104","author":"Welch","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B62","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1096\/fj.07-8582com","article-title":"Demonstrating the C-terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition","volume":"21","author":"Wexler-Cohen","year":"2007","journal-title":"FASEB J."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e1000509","DOI":"10.1371\/journal.ppat.1000509","article-title":"Membrane-anchored HIV-1 N-heptad repeat peptides are highly potent cell fusion inhibitors via an altered mode of action","volume":"5","author":"Wexler-Cohen","year":"2009","journal-title":"PLoS Pathog."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e01839","DOI":"10.1128\/JVI.01839-16","article-title":"A helical short-peptide fusion inhibitor with highly potent activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and simian immunodeficiency virus","volume":"91","author":"Xiong","year":"2017","journal-title":"J. Virol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1128\/AAC.49.3.1113-1119.2005","article-title":"Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41","volume":"49","author":"Xu","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.bbamem.2013.12.022","article-title":"ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer","volume":"1838","author":"Yu","year":"2014","journal-title":"Biochim. Biophys. Acta"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fcimb.2018.00051\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T17:55:19Z","timestamp":1603907719000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fcimb.2018.00051\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,26]]},"references-count":66,"alternative-id":["10.3389\/fcimb.2018.00051"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2018.00051","relation":{},"ISSN":["2235-2988"],"issn-type":[{"type":"electronic","value":"2235-2988"}],"subject":[],"published":{"date-parts":[[2018,2,26]]},"article-number":"51"}}